CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) CEO Thomas P. Mathers sold 1,502 shares of the company’s stock in a transaction dated Wednesday, October 5th. The stock was sold at an average price of $37.08, for a total transaction of $55,694.16. Following the completion of the sale, the chief executive officer now directly owns 248,169 shares of the company’s stock, valued at $9,202,106.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) opened at 36.23 on Monday. The stock’s 50 day moving average is $23.63 and its 200 day moving average is $11.44. CoLucid Pharmaceuticals Inc. has a 12-month low of $3.60 and a 12-month high of $39.27. The firm’s market cap is $555.55 million.
CoLucid Pharmaceuticals (NASDAQ:CLCD) last issued its quarterly earnings data on Wednesday, August 10th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by $0.22. On average, equities research analysts expect that CoLucid Pharmaceuticals Inc. will post ($3.91) EPS for the current year.
A number of research firms recently weighed in on CLCD. Piper Jaffray Cos. set a $49.00 price objective on shares of CoLucid Pharmaceuticals and gave the stock an “overweight” rating in a research note on Friday, September 30th. Ladenburg Thalmann set a $57.00 target price on shares of CoLucid Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, September 19th. Stifel Nicolaus boosted their target price on shares of CoLucid Pharmaceuticals from $27.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, September 19th. Finally, Zacks Investment Research downgraded shares of CoLucid Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 9th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. CoLucid Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $33.05.
Several hedge funds have recently modified their holdings of the company. Societe Generale acquired a new stake in shares of CoLucid Pharmaceuticals during the second quarter worth about $464,000. FMR LLC acquired a new stake in shares of CoLucid Pharmaceuticals during the second quarter worth about $554,000. Finally, Vanguard Group Inc. increased its stake in shares of CoLucid Pharmaceuticals by 1.2% in the second quarter. Vanguard Group Inc. now owns 76,242 shares of the biopharmaceutical company’s stock worth $623,000 after buying an additional 900 shares during the last quarter. 30.47% of the stock is owned by hedge funds and other institutional investors.
About CoLucid Pharmaceuticals
CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.
Receive News & Ratings for CoLucid Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CoLucid Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.